ASCLETIS-B (01672) has announced the successful completion of a placement involving a total of 69.256 million shares on February 10, 2026. The shares were priced at HK$12.18 per share, generating net proceeds of approximately HK$835 million. Approximately 90% of the funds are designated for the preparation, foundational work, and initiation of the global Phase III clinical trials for ASC30, an oral small-molecule GLP-1 receptor agonist intended for the treatment of obesity. The remaining 10% is allocated for working capital and other general corporate purposes.